Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?
- B. Nelson, M. Nalesnik, D. Bahler, J. Locker, J. Fung, S. Swerdlow
- Biology, MedicineAmerican Journal of Surgical Pathology
- 1 March 2000
EBV-negative PTLDs have distinct features, but some do respond to decreased immunosuppression, similar to EBV-positive cases, suggesting that EBV positivity should not be an absolute criterion for the diagnosis of a PTLD.
Liver Transplantation in the United States, 1999–2008
- P. Thuluvath, M. Guidinger, J. Fung, L. Johnson, S. Rayhill, S. Pelletier
- MedicineAmerican Journal of Transplantation
- 1 April 2010
Despite increases in donor and recipient risk factors, there was a trend towards better 1‐year graft and patient survival between 1998 and 2007 and of major concern, however, were considerable regional variations in waiting time and posttransplant survival.
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management
- R. Kowalski, D. Post, A. Zeevi
- Medicine, BiologyClinical Transplantation
- 1 April 2003
Each year, 55,000 organ transplants are performed worldwide, and the number of living organ recipients is now estimated to be over 300,000, with most of these transplant recipients remaining on immunosuppressive drugs for the remainder of their lives to prevent rejection episodes.
Zygomycosis in Solid Organ Transplant Recipients in a Tertiary Transplant Center and Review of the Literature
- N. Almyroudis, D. Sutton, P. Linden, M. Rinaldi, J. Fung, S. Kusne
- MedicineAmerican Journal of Transplantation
- 1 October 2006
While rhino‐sino‐orbital disease had the best prognosis, rhinocerebral disease had high mortality comparable to disseminated disease, and a favorable outcome was associated with limited, surgically accessible disease and early surgical intervention along with amphotericin B administration.
The Incidence, Timing, and Management of Biliary Tract Complications After Orthotopic Liver Transplantation
- F. Greif, O. Bronsther, T. Starzl
- MedicineAnnals of Surgery
- 1 January 1994
Progress has been made on improving the result of biliary reconstruction after OLTx, and if significant additional improvement in patient and graft survival are to be obtained, the technical performance of OLTx must continue to improve.
Immunosuppression: Evolution in Practice and Trends, 1994–2004
- H. Meier‐Kriesche, S. Li, A. Leichtman
- MedicineAmerican Journal of Transplantation
- 1 May 2006
An organ‐by‐organ review of OPTN/SRTR data showed several important trends in immunosuppression practice, including an increasing trend toward the use of induction therapy with antibodies, and maintenance of the original discharge regimen through the first 3 years following transplantation varied significantly by organ and drug.
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system.
- S. Iwatsuki, I. Dvorchik, T. Starzl
- MedicineJournal of the American College of Surgeons
- 1 September 1999
Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial
- P. De Simone, F. Nevens, G. Junge
- MedicineAmerican Journal of Transplantation
- 1 November 2012
Everolimus facilitates early tacrolimus minimization with comparable efficacy and superior renal function, compared to a standard tacro Limus exposure regimen 12 months after liver transplantation, according to a prospective, multicenter, open‐label study.
Long-Term Survival After Liver Transplantation in 4,000 Consecutive Patients at a Single Center
Significantly improved patient and graft survival has been observed over time, and graft loss from acute or chronic rejection has emerged as a rarity.
The spectrum of portal vein thrombosis in liver transplantation.
- A. Stieber, G. Zetti, T. Starzl
- MedicineAnnals of Surgery
- 1 March 1991
It is concluded that a vast majority of the patients with thrombosis of the portal system can be technically transplanted and that their survival rate is comparable to that of patients with patent portal vein.
...
...